Modification of levodopa responses by deprenyl (Selegiline): An electrophysiological and behavioral study in the rat relevant to Parkinson's disease

Nicola B. Mercuri, Mariangela Scarponi, Mauro Federici, Antonello Bonci, Antonio Siniscalchi, Giorgio Bernardi

Research output: Contribution to journalArticlepeer-review

Abstract

From using in vitro intracellular recordings from mesencephalic neurons and monoamine-depleted rats, we report that the functions of levodopa in the brain are greatly enhanced and prolonged by high doses of the monoamine oxidase (MAO) inhibitor deprenyl. Dopaminergic neurons were hyperpolarized and inhibited by levodopa application. These effects of levodopa were largely potentiated by pretreatment with nonselective doses of deprenyl. Furthermore, when locomotor activity induced by levodopa was examined on a rodent model of Parkinson's disease, pretreatment of the animals with nonselective doses of deprenyl caused an enhancement of the antiparkinsonian action of levodopa. The great increase in levodopa responses by deprenyl suggests a likely therapeutic use of this dopamine precursor with a higher dosage of the MAO inhibitor, to reduce effectively the daily levodopa requirements in Parkinson's disease patients.

Original languageEnglish
Pages (from-to)613-617
Number of pages5
JournalAnnals of Neurology
Volume43
Issue number5
DOIs
Publication statusPublished - May 1998

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'Modification of levodopa responses by deprenyl (Selegiline): An electrophysiological and behavioral study in the rat relevant to Parkinson's disease'. Together they form a unique fingerprint.

Cite this